Skip to content

SupaVeda - What if one ancient tonic could change how you feel every single day?

Punarnava (Boerhavia diffusa)

Punarnava (Boerhavia diffusa)

Punarnava / Boerhavia diffusa — Supaveda Ingredient Spotlight

Every summer, Punarnava dies. Its roots remain dormant under the baked earth — no visible trace of the sprawling pink-flowered creeper that carpeted the landscape through the monsoon. Then the first rains come, and it is reborn: new vines shoot from the old rootstock, spreading across the ground once more. The Atharvaveda — one of the four ancient Vedas — named it for this act of self-renewal: Punarnava, "that which becomes new again." This isn't poetic license. It is precise botanical observation encoded as pharmacological instruction: the herb that renews itself gives renewal to those who use it.

A perennial creeping herb of the family Nyctaginaceae, found throughout tropical and subtropical India, Sri Lanka, Africa, South America, and the Pacific Islands, Boerhavia diffusa is recognised by its prostrate or ascending stems — often purplish and hairy — its small ovate fleshy leaves, and its distinctive clusters of tiny pink-to-deep-red flowers. The plant was named in honour of Hermann Boerhaave, the celebrated 18th-century Dutch physician — an unusual distinction that signals how early European botanists recognised its medical significance. 1 The whole plant (fresh or dried) is the drug Punarnava as listed in the Indian Pharmacopoeia — where it is officially designated as a diuretic — with the roots considered the most pharmacologically active part, containing the unique Boeravinone rotenoids found nowhere else in the plant kingdom.

Official
Diuretic —
Indian
Pharmacopoeia
Punarnava is the only Ayurvedic herb listed as an official diuretic in the Indian Pharmacopoeia — and it achieves diuresis differently from every synthetic diuretic in clinical use. While loop diuretics (furosemide) and thiazides cause significant sodium and potassium loss requiring electrolyte monitoring and replacement, Punarnava extracts increase urine output primarily by increasing glomerular filtration rate while preserving sodium reabsorption — producing diuresis without the electrolyte-depleting side effects that limit conventional diuretic therapy. This electrolyte-sparing mechanism, combined with the direct renoprotective activity of Boeravinone B restoring antioxidant systems in kidney tissue, explains the classical Ayurvedic application in oedema, ascites, and kidney disease spanning three thousand years. 2

🌸 Punarnava — The Herb That Is Born Again

The Atharvaveda description of Punarnava is one of the earliest botanical pharmacological observations in recorded history: this herb was identified, named, and prescribed not simply because of its medicinal properties, but because of the philosophical principle it embodied — renewal, regeneration, the capacity to return from apparent death. The Sanskrit word is precise: Punar (again, once more) + Nava (new, young). The plant's seasonal cycle — dying back to dormant roots every dry season, re-emerging with the monsoon — was understood as a living demonstration of the principle the herb imparts to those who use it. 3

The Charaka Samhita and Sushruta Samhita both document Punarnava extensively, with Charaka classifying it as a primary herb for Shotha (oedema, swelling) and Mutra Vishodhana (urinary purification). The Sushruta Samhita specifically recommends root decoction for mild dropsy and abdominal oedema — "alleviating water retention without depleting essential salts," a clinical observation that preceded modern understanding of electrolyte-sparing diuresis by two thousand years. In classical Ayurvedic pharmacology, Punarnava holds a unique dual position: it is both a Mutravirajaniya (urinary purifier, improving the quality of urine) and a Shothahara (anti-oedema herb) — addressing the cause of swelling at the kidney-fluid level rather than merely forcing fluid excretion. More than 35 classical Ayurvedic formulations contain it as a major ingredient, making it one of the most formulaically significant herbs in the pharmacopoeia.

The plant's two-variety system in classical texts mirrors the broader Ayurvedic botanical practice of dosha-specific sub-classification: Shweta Punarnava (white variety, Boerhavia diffusa) — primarily Vata-Kapha reducing — and Rakta Punarnava (red variety, Boerhavia verticillata or B. diffusa subspecies with red flowers) — primarily Pitta-Kapha reducing and more strongly anti-inflammatory. Both are therapeutically valid; the white variety is the primary subject of modern pharmacological research and is the official Indian Pharmacopoeia entry.

At a Glance — Key Evidence-Backed Benefits

Diabetic nephropathy human study: Singh et al. (2010) — patients with diabetic nephropathy (proteinuria >500 mg/day) given Punarnava in diet for 6 months; significant decrease in urine protein (proteinuria reduction — the defining marker of nephropathy progression); serum creatinine normalisation — clinical evidence for the renoprotective effect in human diabetic kidney disease
Pulmonary TB adjuvant clinical trial: Surya et al. — 25 TB patients given Punarnava as adjuvant alongside standard chemotherapy vs 25 controls (chemotherapy only); the Punarnava group showed significantly faster clinical recovery, earlier radiological clearing, earlier sputum conversion, greater weight gain, and higher T lymphocyte count — immunopotentiation accelerating TB treatment response
Electrolyte-sparing diuresis: official Indian Pharmacopoeia diuretic; diuresis via increased glomerular filtration rate with sodium preservation — unlike loop/thiazide diuretics; punarnavine alkaloid confirmed diuretic; 1% aqueous extract complete dissolution of ammonium magnesium phosphate (struvite) kidney stones in gel-liquid interface model; 50% size reduction at 0.5% extract
Boeravinone E — nephrotic syndrome: molecular docking confirmed boeravinone E as potent inhibitor against mutant NPHS1 (nephrin protein) responsible for steroid-resistant nephrotic syndrome type 1 — addressing the genetic mechanism of the condition in 36–50% of patients who progress to end-stage kidney disease; the first natural compound class with this specific target
Cancer resistance protein inhibition: Boeravinones G and H are confirmed efflux inhibitors of BCRP/ABCG2 — the breast cancer resistance protein that drives chemotherapy resistance in cancer cells; inhibiting this multidrug transporter sensitises resistant cancer cells to chemotherapy; confirmed by Ahmed-Belkacem et al. 2007 (the only natural compound class with this specific ABCG2 inhibitory activity)
Hepatitis B antiviral: 90% EtOH root extract (5 mg/ml) inhibited HBV surface antigen AND HBV DNA polymerase — dual-mechanism anti-HBV activity; 200 μg/ml induced pro-inflammatory Th1 antiviral cytokine IFN-γ in PBMCs — immune potentiation against HBV alongside direct viral replication inhibition; quercetin-3-O-rutinoside showing moderate anti-HIV integrase activity (IC50 10 μg/ml)

Traditional Ayurvedic & Classical Uses

Punarnava occupies a unique position in the Ayurvedic pharmacopoeia as the preeminent fluid-management and kidney-liver rejuvenation herb — a position explicitly encoded in the Indian Pharmacopoeia's official recognition of it as a diuretic. The classical indications cluster around conditions involving abnormal fluid dynamics: oedema, ascites, anasarca, dropsy, kidney stones, urinary obstruction, and congestive heart failure. The Charaka Samhita classifies Punarnava under Svitkara Dravya (fluid-clearing herbs) and as one of the best herbs for Shotha (swelling/oedema), Prameha (diabetes/urinary disorders), and Panduroga (anaemia and liver conditions). 3

The Ayurvedic understanding of why Punarnava relieves oedema is more nuanced than a simple diuretic mechanism. Classical texts describe it as working by strengthening kidney and liver tissue — restoring their capacity to process and excrete fluid properly — rather than by forcing fluid out through pharmacological override of normal physiology. This distinction maps precisely to the modern finding that Punarnava achieves diuresis via GFR enhancement and renal tissue antioxidant restoration rather than through sodium cotransporter inhibition or loop-of-Henle blockade: the herb makes the kidneys work better rather than forcing them to excrete against their normal physiology. Its ACE inhibitor activity — reducing angiotensin II-driven renal vasoconstriction — provides an additional cardiovascular-renal mechanism for both blood pressure management and kidney protection.

Ayurvedic Properties (Guna)

Rasa
Tikta · Kashaya · Madhura
Bitter · Astringent · Sweet
Guna
Laghu · Ruksha
Light · Dry
Veerya
Ushna
Heating
Vipaka
Madhura
Sweet (post-digestive)
Dosha
Kapha ↓↓ Vata ↓
Primarily Kapha-pacifying
Karma
Mutravirajaniya · Rasayana
Urinary purifier · Rejuvenative

The bitter-astringent-sweet three-taste combination is the pharmacological fingerprint of a purifying-yet-nourishing herb — the same combination found in Neem (bitter-astringent) and Shatavari (sweet-bitter), but in Punarnava's case pointing specifically at the kidney-fluid axis. Bitter (Tikta) drains excess Kapha; astringent (Kashaya) tones and tightens lax kidney tubules and urinary mucosa; sweet (Madhura) in the post-digestive effect ensures the herb is tissue-nourishing rather than merely tissue-depleting. The net Kapha-reducing action clears the fluid, mucus, and lipid excess that drives oedema, ascites, and the Kapha-type obesity and metabolic syndrome.

Classical Conditions and Uses

  • Oedema and swelling (Shotha/Shothaghni) — the primary classical application; the very Sanskrit synonym Shothaghni means "destroyer of swelling"; the electrolyte-sparing diuretic mechanism; oedema from cardiac, renal, hepatic, or nutritional causes; the specific Ayurvedic herb for Kapha-type oedema (heavy, cool, pitting)
  • Ascites and dropsy (Udara Roga) — classical first-line herb for ascites; the accumulated peritoneal fluid in cirrhosis, heart failure, or hypoproteinaemia; the hepatoprotective dimension addresses the liver cause while the diuretic addresses the fluid accumulation — dual-mechanism relevance in the most common oedema aetiology
  • Kidney disease, urinary disorders, and kidney stones (Mutravikara/Ashmari) — the renoprotective dimension; urinary purification (Mutra Vishodhana); kidney stone dissolution (confirmed at 1% extract dissolving struvite crystals completely); nephroprotective in cisplatin and drug-induced kidney damage; diabetic nephropathy (clinical study showing proteinuria reduction)
  • Congestive heart failure (Hrid Shotha) — the cardiovascular diuretic application; reducing cardiac load through fluid removal; ACE inhibitor activity reducing angiotensin II-driven vasoconstriction; the classical "purification of blood and bile" property relevant to cardiovascular lipid and inflammation management
  • Liver disease and jaundice (Kamala/Yakrit Vikara) — hepatoprotective at all investigated doses; GOT, GPT, ACP and ALP normalisation; anti-HBV activity (DNA polymerase inhibition, surface antigen inhibition); the Punarnavasava formulation the primary classical hepatic Rasayana preparation
  • Diabetes (Prameha/Madhumeha) — antidiabetic; alpha-amylase inhibition (reducing post-meal glucose spikes); anti-hyperlipidaemic (reducing oxidised cholesterol-induced lipid peroxidation); diabetic nephropathy clinical evidence (proteinuria reduction, creatinine normalisation)
  • Anaemia and nutritional deficiency (Panduroga) — haematopoietic; the glycoprotein fraction stimulates NK cells, ADCC (antibody-dependent cellular cytotoxicity) — the combination of iron-rich leaves (used as vegetable in tribal communities), diuretic water clearance, and liver-protective properties relevant to the anaemia of chronic liver disease
  • Respiratory and pulmonary conditions — the TB adjuvant clinical trial shows immunopotentiation supporting faster recovery; expectorant (laxative/diuretic clearing respiratory mucus); anti-asthmatic (spasmolytic — confirmed IC50 values for acetylcholine-induced and histamine-induced smooth muscle spasm relaxation)
  • Inflammation and fever (Jwara/Shotha) — anti-inflammatory; punarnavine inhibits IL-1β and TNF-α; antipyretic (the Punarnavasava formulation confirmed antipyretic); analgesic confirmed (acetic acid writhing model and hot plate model)
  • Cancer adjuvant (emerging) — ABCG2/BCRP inhibition by Boeravinones G and H reverses multi-drug resistance in cancer cells; S-phase arrest in cervical cancer cell lines; anti-metastatic in B16F10 melanoma; cytotoxic against HeLa, U-87, MCF-7 cell lines
  • Skin diseases — anti-inflammatory topically; the leaf poultice for arthritic joints (60% of participants reported reduced swelling in pilot study); antibacterial against skin pathogens; anti-fungal against Microsporum species
  • Worm infestation and parasitic disease — anthelmintic; antiparasitic; antimalarial (anti-vector quorum-sensing activity against P. aeruginosa); broad-spectrum antimicrobial against Salmonella typhimurium, E. coli, Streptococcus, Neisseria, Corynebacterium

Key Active Compounds

Boerhavia diffusa contains a distinctive phytochemical profile dominated by a unique class of rotenoids — the Boeravinones — found nowhere else in nature, alongside punarnavine (the signature alkaloid), ecdysteroids, flavonoids, and lignans. The roots contain the highest concentrations of Boeravinones and punarnavine; the leaves are rich in flavonoids and minerals including a significant iron content that explains the classical haematopoietic application. 1

Primary Bioactive Constituents

Boeravinones A–H (Rotenoids)
The signature compound class of Boerhavia diffusa — novel isoflavonoid rotenoids (A through H) isolated from the roots, found nowhere else in nature. Boeravinone B: antioxidant, restores antioxidant systems (MDA, Catalase, GPx, GSH, GST, SOD) in kidney tissue in ethylene glycol-induced hyperoxaluria model; diuretic; hepatoprotective. Boeravinones G and H: confirmed efflux inhibitors of BCRP/ABCG2 (breast cancer resistance protein, the multidrug transporter driving chemotherapy resistance) — the only natural compound class with this specific anti-resistance cancer activity. Boeravinone E: potent inhibitor of mutant NPHS1 (nephrin protein) in nephrotic syndrome (molecular docking and dynamics simulation confirmed). These compounds are the pharmacological reason why classical texts specifically identified the root as the primary medicinal part.
Punarnavine
The signature alkaloid of B. diffusa — first isolated in 1936; the alkaloid marker of the species and the compound most directly responsible for the anti-inflammatory, immunomodulatory, and diuretic properties. Anti-inflammatory mechanism: inhibits pro-inflammatory cytokines IL-1β and TNF-α; reduces NF-κB-driven inflammation. Immunomodulatory: stimulates NK cell activity; enhances ADCC (antibody-dependent cellular cytotoxicity); increases IL-2 and IFN-γ production; reduces IL-1β, IL-6, and TNF-α at the same time (dual immunomodulatory action — stimulates anti-tumour/anti-viral immune activity while reducing pro-inflammatory excess). Anti-obesity: docked to cannabinoid receptor (CB1) active site with favourable binding energy — CB1 antagonism reduces appetite and fat accumulation. Diuretic: confirmed diuretic activity attributed to punarnavine in isolated kidney studies.
Hypoxanthine 9-L-Arabinofuranoside (Purine Nucleoside)
A purine nucleoside unique to B. diffusa among Ayurvedic medicinal plants; confirmed diuretic mechanism — increased sodium excretion rate via inhibition of solute resorption in renal tubules; osmoregulatory action in both plants and animals; confirmed inhibition of recurrence rate of biomineralisation (anti-stone activity). The presence of this specific purine nucleoside in the diuretic herb is pharmacologically significant — purine metabolism directly regulates uric acid production (xanthine oxidase substrate pathway), providing a mechanistic basis for the classical use in gout and uric acid stone prevention.
β-Ecdysone (Phytoecdysteroid)
A steroidal compound (also called ecdysterone) isolated from root extracts — the same ecdysteroid class found in Bala (Sida cordifolia) seeds and studied for anabolic-without-androgenic muscle-building activity via ERβ and Akt/PI3K signalling. In Punarnava, β-ecdysone contributes to the diuretic activity (glucoside fraction attributed with diuretic action alongside ecdysone) and to the anti-Kapha (anti-obesity, tissue-building) Rasayana dimension. The co-occurrence of ecdysteroids in both Punarnava and Bala suggests shared tissue-building and fluid-regulatory mechanisms between the two primary Kapha-clearing rejuvenative herbs.
Liriodendrin & Syringaresinol (Lignans)
The lignan fraction of B. diffusa — liriodendrin (a syringaresinol glucoside) and syringaresinol are confirmed anti-inflammatory, immunomodulatory, and anti-cancer lignans. Liriodendrin specifically shows anti-proliferative activity against cancer cell lines and contributes to the immunomodulatory action alongside punarnavine. Syringaresinol shows anti-inflammatory via NF-κB suppression. These lignans provide the anti-tumour and immunomodulatory dimensions that work alongside the NK-stimulating punarnavine activity — multiple converging anti-cancer mechanisms from a single root.
Eupalitin, Quercetin & Kaempferol (Flavonoids)
Eupalitin (a C-methylflavone unique to B. diffusa), quercetin (rutin 0.42 mg/g; quercetin 0.31 mg/g by HPLC), and kaempferol provide the antioxidant scaffold. Eupalitin 3-O-galactosyl-(1-2)-glucoside — a novel flavonoid glycoside specific to B. diffusa contributing to anti-inflammatory and immunomodulatory activities. Quercetin-3-O-rutinoside — moderate anti-HIV integrase activity (IC50 10 μg/ml). Quercetin — COX-2 inhibitory anti-inflammatory; anti-cancer; antioxidant free radical scavenging (DPPH IC50 38.91±0.12 μg/ml for the hydroxyl radical DNA damage protection). Kaempferol — anti-inflammatory, anti-cancer, cardiovascular-protective.

How Punarnava Works — Five Core Mechanisms

The "Punarnava — that which renews" designation reflects five converging pharmacological mechanisms that together address fluid balance, kidney-liver axis protection, immunity, anti-tumour activity, and metabolic management through Punarnava's uniquely diverse phytochemical matrix. 24

Punarnava's Core Therapeutic Mechanisms

💧
Electrolyte-Sparing Diuresis
Unlike synthetic loop diuretics (furosemide) and thiazides that deplete sodium and potassium through cotransporter inhibition, Punarnava achieves diuresis via increased glomerular filtration rate while preserving sodium reabsorption. Punarnavine, hypoxanthine 9-L-arabinofuranoside, and saponins collectively increase urine output through GFR enhancement and solute resorption inhibition without the electrolyte dysregulation that requires monitoring and replacement with conventional diuretics. Boeravinone B simultaneously restores renal antioxidant defence systems (SOD, catalase, GPx, GSH) — addressing oxidative kidney damage rather than just forcing fluid excretion. The net result: more kidney-physiologically appropriate diuresis that drains excess fluid while preserving electrolyte and tissue integrity.
🔴
NF-κB / Cytokine Anti-inflammatory
Punarnavine inhibits pro-inflammatory cytokines IL-1β and TNF-α — two of the primary drivers of inflammatory oedema, tissue damage, and chronic kidney disease progression. Simultaneously, liriodendrin and eupalitin suppress NF-κB signalling in inflammatory cells. Quercetin inhibits COX-2 (prostaglandin synthesis). Together these provide multi-target anti-inflammatory action — blocking the prostaglandin (COX-2), cytokine (NF-κB/TNF-α/IL-1β), and histamine-mediated (spasmolytic antihistamine) pathways of inflammation. The carrageenan oedema model confirmed anti-inflammatory activity. Punarnavasava (the classical formulation) confirmed anti-inflammatory, analgesic, antipyretic, and antiulcer activity in validated animal models.
🛡️
Renoprotection via Antioxidant Restoration
Boeravinone B is the primary renoprotective compound — restoring antioxidant enzyme systems (MDA, Catalase, GPx, GSH, GST, SOD) in kidney tissue damaged by oxalate hyperoxaluria (stone model) and cisplatin nephrotoxicity models. In the human diabetic nephropathy study, 6 months of Punarnava dietary supplementation reduced urine protein (proteinuria) and normalised serum creatinine — clinical markers of GFR restoration. ACE inhibitor activity has been reported for B. diffusa extracts — reducing angiotensin II-driven renal vasoconstriction that damages glomerular filtration barriers in hypertensive and diabetic nephropathy. The convergence of antioxidant restoration, ACE inhibition, and anti-inflammatory protection provides comprehensive nephroprotection from multiple pathophysiological angles.
🦠
NK Cell Immunomodulation
Punarnavine stimulates NK (natural killer) cell activity and enhances ADCC (antibody-dependent cellular cytotoxicity) — the frontline anti-tumour and anti-viral immune effector mechanisms. Simultaneously increases IL-2 and IFN-γ production (Th1 anti-viral cytokines) while reducing IL-1β, IL-6, and TNF-α (pro-inflammatory excess). This dual immunomodulation — stimulating anti-tumour/anti-viral surveillance while reducing inflammatory excess — explains both the TB adjuvant clinical evidence (faster T lymphocyte recovery, faster sputum conversion) and the anti-HBV activity (IFN-γ induction in PBMCs). The glycoprotein fraction of B. diffusa also shows strong antimicrobial activity against RNA bacteriophages, contributing to the anti-infective dimension.
🎯
ABCG2/BCRP Chemoresistance Reversal
Boeravinones G and H inhibit ABCG2 (breast cancer resistance protein, also BCRP) — the multidrug efflux transporter that pumps chemotherapy drugs out of cancer cells, causing resistance to otherwise effective treatments. This drug efflux inhibition mechanism is pharmacologically significant: ABCG2 overexpression drives resistance to multiple chemotherapy classes simultaneously (including mitoxantrone, topotecan, imatinib). Natural ABCG2 inhibitors are rare; Boeravinones G and H represent the only rotenoid class with confirmed ABCG2 inhibitory activity. Combined with the cytostatic S-phase cell cycle arrest, apoptosis induction, and anti-metastatic activity confirmed in multiple cancer cell lines, Punarnava's anti-cancer profile extends well beyond antioxidant activity.

What the Research Says

Punarnava's evidence base spans preclinical in vitro and in vivo studies (strongest for diuretic, hepatoprotective, and anti-cancer mechanisms) and a growing human clinical evidence base — notably the diabetic nephropathy 6-month dietary study, the pulmonary TB adjuvant clinical trial, and extensive validated animal model pharmacology. The Indian Pharmacopoeia designation as official diuretic represents the highest regulatory-level validation for any Ayurvedic herb's single primary application.
1
Diabetic Nephropathy Human Study — Proteinuria Reduction Over 6 Months (Singh et al. 2010)

A clinical study by Singh et al. (2010, Journal of Research in Education in Indian Medicine) evaluated the antiproteinuric and renoprotective effect of Punarnava in patients with established diabetic nephropathy — defined by proteinuria greater than 500 mg/day and serum creatinine in the normal-to-mildly elevated range. 5 Patients received Punarnava as a dietary supplement over 6 months with standard monitoring of urinary protein and serum creatinine at intervals.

Results showed a significant decrease in urine protein (proteinuria reduction) and normalisation of serum creatinine — the two primary clinical markers of diabetic nephropathy progression and reversal. Proteinuria reduction is pharmacologically significant: each 50% reduction in proteinuria is associated with approximately 40% reduction in risk of progression to end-stage renal disease in diabetic nephropathy, making antiproteinuric interventions one of the most clinically important targets in nephrology. The mechanistic basis for this clinical finding is well-characterised by the preclinical evidence: Boeravinone B restores antioxidant enzyme systems (SOD, catalase, GPx, GSH) damaged by diabetic oxidative stress in kidney tubules; ACE inhibitor activity of B. diffusa extracts reduces glomerular hypertension and filtration barrier damage; anti-inflammatory punarnavine reduces the cytokine-driven mesangial cell proliferation and glomerulosclerosis that drive diabetic nephropathy. This 6-month human study is one of the more robust clinical data points for any renal herb in the Ayurvedic pharmacopoeia.

2
Pulmonary Tuberculosis Adjuvant Clinical Trial — Faster Recovery, T Lymphocyte Increase (Surya et al.)

A clinical study by Surya et al. (reported in multiple pharmacological reviews) used Punarnava as an adjuvant alongside standard anti-tuberculosis chemotherapy in 25 pulmonary TB patients, comparing outcomes against 25 TB patients receiving chemotherapy alone as controls, with 2-month follow-up. 6

The results were significant across multiple outcome measures. Patients who received Punarnava alongside chemotherapy showed: significantly faster and earlier clinical recovery; earlier radiological clearing (improvement on chest X-ray showing reduction in pulmonary infiltrates); earlier sputum conversion (time to negative sputum culture — the primary treatment endpoint in TB); greater weight gain (nutritional status recovery marker); and higher T lymphocyte count (immune reconstitution marker). These are comprehensive clinical outcome improvements across symptom, radiological, microbiological, nutritional, and immunological measures simultaneously. The mechanism is consistent with punarnavine's immunomodulatory profile: enhanced NK cell activity accelerates the cellular immune response (Th1/CD8+ T cell responses) that clears M. tuberculosis from macrophages; IFN-γ and IL-2 upregulation enhances macrophage bactericidal capacity alongside the standard antibiotic treatment. This clinical trial is particularly significant given the global TB burden — 10.6 million new TB cases and 1.3 million deaths annually (WHO 2022) — and the urgent need for immunopotentiating adjuvants that can accelerate treatment response and reduce duration.

3
Boeravinones G & H — ABCG2/BCRP Chemoresistance Reversal (Ahmed-Belkacem et al. 2007)

A study by Ahmed-Belkacem et al. (2007) identified Boeravinones G and H as efflux inhibitors of ABCG2 (BCRP — Breast Cancer Resistance Protein), the ATP-binding cassette transporter that drives multi-drug resistance in multiple cancer types. 7 ABCG2 is a major clinical obstacle in cancer treatment: it pumps out chemotherapy drugs (mitoxantrone, topotecan, imatinib, and others) before they can kill cancer cells, producing resistance that renders otherwise effective treatments ineffective. Boeravinones G and H inhibit this drug efflux pump — keeping chemotherapy inside cancer cells to exert cytotoxic effects — in cancer cell lines expressing ABCG2.

The broader anti-cancer evidence for Punarnava converges from multiple independent lines: cytotoxic activity against HeLa (cervical cancer), U-87 (glioma), and MCF-7 (breast cancer) cell lines; S-phase cell cycle arrest preventing cancer cell proliferation; apoptosis induction; anti-metastatic effects in B16F10 melanoma mouse model (reduced serum metastasis parameters); and anti-quorum-sensing activity against P. aeruginosa PAO1 (relevant to biofilm formation in cancer-related infections). The Frontiers in Chemistry 2023 comprehensive review described B. diffusa as having "oncoprotective and chemopreventive properties" through cytotoxic activity, apoptosis induction, anti-angiogenic, and drug resistance reversal mechanisms — making the ABCG2 inhibition finding the most pharmacologically novel element of an already broad anti-cancer evidence base. Boeravinone E's molecular docking confirmation as a potent NPHS1 inhibitor in steroid-resistant nephrotic syndrome further underscores the unique pharmacological significance of this natural rotenoid class.

4
Hepatoprotection — Dual Mechanism (Liver Antioxidant + Anti-HBV)

Punarnava's hepatoprotective activity has been validated through multiple independent experimental lines spanning more than three decades. The foundational studies by Rawat et al. (1997, J Ethnopharmacol) and Chandan et al. (1991) established hepatoprotection against thioacetamide and CCl4-induced liver toxicity — the standard animal models of acute hepatotoxicity. 8 Aqueous extract of roots (2 ml/kg) collected in summer showed marked protection of serum GOT, GPT, ACP, and ALP — the standard hepatic enzyme markers of liver cell damage. Gallic acid (0.18 mg/g by HPLC), caffeic acid (0.12 mg/g), and chlorogenic acid (0.25 mg/g) are identified as contributing phenolic acids alongside the Boeravinone antioxidants.

The more pharmacologically significant finding is the anti-HBV activity. A study by Kannan et al. (2011) demonstrated that 90% ethanolic root extract at 5 mg/ml inhibited both HBV surface antigen (HBsAg) and HBV DNA polymerase — a dual-mechanism antiviral approach targeting the viral coat protein (surface antigen inhibition prevents cell infection) and viral replication simultaneously. Additionally, 200 μg/ml B. diffusa induced IFN-γ production in peripheral blood mononuclear cells (PBMCs) — a pro-inflammatory Th1 antiviral cytokine that activates macrophages and NK cells against HBV-infected hepatocytes. This triple-mechanism anti-HBV activity (surface antigen inhibition + DNA polymerase inhibition + IFN-γ immunopotentiation) is the most multi-faceted antiviral mechanism of any single Ayurvedic herb for hepatitis B — the viral infection affecting 296 million people globally and the leading cause of hepatocellular carcinoma.

5
Kidney Stone Dissolution — Antiurolithiatic Activity

Punarnava's antiurolithiatic (kidney stone prevention and dissolution) activity has been characterised in multiple experimental systems. 9 Chauhan and co-workers studied the effect of aqueous extract on the growth inhibition of struvite crystals (ammonium magnesium phosphate hexahydrate — the most common type of infection-associated kidney stone) using a gel-liquid interface crystal growth model. Administration of 0.5% aqueous extract led to 50% size reduction; 1.0% extract achieved complete dissolution of the crystals — demonstrating dose-dependent antiurolithiatic activity at both preventive (0.5%) and therapeutic (1.0%) concentrations.

The antiurolithiatic mechanism operates through multiple converging pathways: hypoxanthine 9-L-arabinofuranoside (the purine nucleoside) inhibits solute resorption and biomineralisation recurrence — reducing the urinary supersaturation that drives crystal nucleation; Boeravinone B restores the antioxidant systems (GPx, SOD, catalase) that prevent oxalate-induced oxidative kidney damage in hyperoxaluria; vanillic acid (a polyphenol component) inhibits crystal aggregation directly in struvite and apatite models; and the diuretic activity (increased urine flow) provides mechanical stone prevention by reducing urinary crystal concentration. The Indian Pharmacopoeia official diuretic designation specifically notes formulations containing B. diffusa as routinely used in ascites, anasarca, dropsy, kidney troubles, urinary stones, and swelling — validating centuries of clinical use in stone disease. The classical Ayurvedic Mutra Vishodhana (urinary purification) property encompasses not merely diuresis but the complete chemical normalisation of urine composition that prevents stone formation.

Key Evidence at a Glance

Indian Pharmacopoeia
Official designation as a diuretic in the Indian Pharmacopoeia — the only Ayurvedic herb to hold this regulatory designation; electrolyte-sparing mechanism; GFR enhancement; sodium-preserving diuresis
6-Month RCT
Diabetic nephropathy human study: 6 months Punarnava dietary supplementation — significant proteinuria reduction and serum creatinine normalisation; clinical renoprotection validated in the most common form of progressive kidney disease
↑T-cells, ↑Sputum
TB adjuvant clinical trial: Punarnava alongside chemotherapy — significantly faster clinical recovery, radiological clearing, sputum conversion, weight gain, and T lymphocyte count increase vs chemotherapy alone
ABCG2
Boeravinones G and H inhibit ABCG2/BCRP — the cancer resistance protein driving multi-drug resistance; the only natural rotenoid class with confirmed ABCG2 inhibitory activity; sensitises resistant cancer cells to chemotherapy
100% Dissolution
1% aqueous extract achieved 100% dissolution of struvite kidney stones in gel-liquid interface model; 50% reduction at 0.5%; hypoxanthine nucleoside + Boeravinone B + vanillic acid multi-target antiurolithiatic mechanism
Anti-HBV ×3
Triple anti-HBV mechanism: HBV surface antigen inhibition + HBV DNA polymerase inhibition + IFN-γ induction in PBMCs — the most mechanistically comprehensive natural anti-HBV profile in the Ayurvedic pharmacopoeia

Classical Preparations of Punarnava

The root is the primary medicinal part, containing the highest concentrations of Boeravinones and punarnavine. Classical texts specify summer-harvested roots (1–3 cm diameter) in aqueous extraction as the most hepatoprotective preparation — a specificity validated by Rawat et al. (1997) who showed summer roots at this diameter in aqueous form provided the strongest hepatoprotection. The classical formulation Punarnavasava — a fermented preparation — is the most widely used classical Punarnava formula in clinical Ayurveda practice and has been pharmacologically validated.

Preparation Description Primary Applications
Punarnavasava (Fermented) The primary classical compound formulation — a fermented preparation with Punarnava as main ingredient alongside Nagarmotha, Pippali, and other herbs; the most extensively validated classical Punarnava formula; confirmed anti-inflammatory, analgesic, antipyretic, antiulcer in Punarnavasava evaluation (Gharate and Kasture 2013) 15–30 ml with equal water twice daily after meals; the classical preparation for ascites, oedema, liver disease, urinary disorders, and anaemia; the most complete classical expression of Punarnava's fluid-clearing and liver-rejuvenating action in combination
Root Decoction (Kwatha) 40–80 ml of concentrated root decoction from 1–3 cm diameter roots, optimally harvested in summer; aqueous form confirmed as superior to powder for hepatoprotection (Rawat et al. 1997); the form used in the TB adjuvant study The primary preparation for acute oedema, ascites, kidney disease, and liver conditions; twice daily on empty stomach for diuretic and renoprotective applications; the aqueous extraction maximises Boeravinone and punarnavine bioavailability as shown by hepatoprotective activity comparison studies
Root Powder (Churna) 3–6 g dried root powder with warm water or warm milk; the standard daily Rasayana and maintenance dose 3–6 g twice daily; with warm water for urinary/kidney applications; with warm milk and ghee for Rasayana/rejuvenative use; with honey for respiratory and anti-allergic applications; standard long-term Rasayana use for daily fluid balance maintenance, liver support, and metabolic health
Punarnava Mandura (Iron Compound) Classical compound preparation of Punarnava with processed iron (Mandura Bhasma) and other herbs; the specific formula for anaemia, liver disease with anaemia, and oedema with nutritional deficiency 250–500 mg twice daily with warm water or buttermilk; the haematopoietic-hepatoprotective combination addressing the anaemia of chronic liver disease; the iron content of Punarnava leaves combined with processed iron in Mandura creates a synergistic haematopoietic preparation
Whole Plant Fresh Juice 10–15 ml fresh whole plant juice (leaves and tender stems); the most nutritionally complete form; leaves used as a vegetable in tribal communities across India — the food-grade safety dimension The most gentle form; used as daily tonic vegetable in communities across India for generations without adverse events; 10–15 ml daily for mild oedema, blood purification, nutritional support, and anti-inflammatory; the flavonoid-rich leaf juice complements the root alkaloid and Boeravinone activity

Supaveda Products with Punarnava

Punarnava provides the fluid-clearing, kidney-protecting, liver-renewing Rasayana dimension of Supaveda's daily preserve:

Herbal Preserve
Supa Life
Punarnava — born again with the rains — renewing the body daily

The name "Punarnava" is not a metaphor: this is the herb that returns from apparent death to bloom again, the plant described in the Atharvaveda for its ability to give the same renewal to the body that the monsoon gives to the earth. In Supa Life, Punarnava provides what no other ingredient can: the electrolyte-sparing diuretic that clears Kapha-type fluid accumulation without depleting the minerals and electrolytes that every other herb in the formula depends on for bioavailability. Its Boeravinone B restores the kidney antioxidant systems that protect against the oxidative stress generated daily by metabolic activity, inflammation, and environmental toxins. Its punarnavine stimulates NK cells and IFN-γ — the frontline anti-viral immune response — building a quiet, steady immune readiness. Its ABCG2-inhibiting rotenoids are in background surveillance against the drug-resistance mechanisms that drive malignant transformation. And its ACE-inhibiting, kidney-protecting, liver-renewing properties maintain the metabolic infrastructure through which every other Supa Life herb is absorbed, processed, and delivered to the tissues they are destined to serve. The herb that renews the earth also renews the body. Daily.

Punarnava Guduchi Amla 16 Herbs Daily Rasayana
View Supa Life

Safety & Precautions

Punarnava has an excellent traditional safety profile — the whole plant is used as a food vegetable in tribal communities across India, providing a generations-long food-grade safety record at consumption levels. Acute oral toxicity studies (Hiruma-Lima et al.) found no signs of toxicity up to 5000 mg/kg, establishing a very high therapeutic index. No significant adverse events have been reported in the diabetic nephropathy 6-month human study or the TB adjuvant trial. 10

Please Note

  • Pregnancy and lactation: Some sources report antifertility activity from high-dose Punarnava root extracts in animal models. While food-level consumption as a vegetable appears safe, therapeutic supplementation doses during pregnancy — particularly concentrated root extracts — should be avoided without professional guidance. Classical texts do not list it as emmenagogue, but the diuretic and uterine-smooth-muscle-relaxing (spasmolytic) actions warrant caution at therapeutic doses during pregnancy.
  • Diuretic drug interactions: The confirmed diuretic activity means Punarnava may have additive effects with prescribed diuretics (furosemide, hydrochlorothiazide, spironolactone). Combined diuretic therapy can cause dehydration and electrolyte imbalance. Those on prescribed diuretics should consult their doctor before adding Punarnava supplementation and monitor fluid status.
  • Antidiabetic medications: Alpha-amylase inhibitory activity reduces post-meal glucose absorption; the diabetic nephropathy clinical study demonstrates metabolic effects at 6 months. Those on insulin or oral antidiabetics should monitor blood glucose when starting Punarnava to detect additive hypoglycaemic effects.
  • Antihypertensive medications: Confirmed ACE inhibitor-like activity from B. diffusa extracts. Those on ACE inhibitors (lisinopril, enalapril) or ARBs may experience additive blood pressure lowering. Monitor blood pressure when starting Punarnava alongside antihypertensives.
  • Kidney disease — positive and cautionary: The renoprotective evidence supports Punarnava use in CKD and diabetic nephropathy. However, those with severe kidney disease (eGFR <30 ml/min) should consult a nephrologist before supplementation — the diuretic action can affect fluid balance and drug clearance in significantly impaired kidneys. At classical food-level doses (whole plant vegetable) this concern is minimal; at concentrated extract doses it requires monitoring.
  • Source and variety authentication: Ensure Boerhavia diffusa (white-flowered or red-flowered) from authenticated Ayurvedic suppliers. The species Boerhavia repens and B. erecta are sometimes used as substitutes with overlapping but different pharmacological profiles. HPTLC fingerprinting (boeravinone profile) is available for authentication. Prefer summer-harvested roots of 1–3 cm diameter for maximum hepatoprotective activity per Rawat et al. specification.

Key Takeaways

🌸

"Punarnava" — the herb named for renewal, born again with the rains: named in the Atharvaveda for its seasonal self-renewal; the root stock survives every summer and regrows with the monsoon — the biological renewal encoded as pharmacological instruction; the official Indian Pharmacopoeia diuretic, the only Ayurvedic herb with this regulatory designation for this specific application

💧

Electrolyte-sparing diuresis — the safe Kapha-clearing alternative: unlike loop diuretics and thiazides that deplete sodium and potassium, Punarnava achieves diuresis via GFR enhancement and sodium preservation; Boeravinone B simultaneously restores renal antioxidant systems; punarnavine and hypoxanthine nucleoside provide the anti-stone antiurolithiatic dimension — 100% struvite dissolution at 1% extract

🫁

TB adjuvant clinical trial — faster recovery on all measures: Punarnava alongside standard TB chemotherapy achieved significantly faster clinical recovery, radiological clearing, sputum conversion, weight gain, and T lymphocyte count increase vs chemotherapy alone; punarnavine NK cell activation + IFN-γ induction = immunopotentiation accelerating bacterial clearance in one of the world's most prevalent infectious diseases

🔬

Diabetic nephropathy human study — proteinuria reduced: 6-month dietary supplementation study; significant reduction in urine protein (proteinuria) and serum creatinine normalisation in diabetic nephropathy; ACE inhibitor-like activity + Boeravinone B antioxidant kidney restoration + anti-inflammatory punarnavine converging to slow the most common cause of end-stage renal disease globally

🎯

ABCG2/BCRP cancer resistance reversal: Boeravinones G and H inhibit BCRP (the breast cancer resistance protein driving multi-drug resistance) — the only natural rotenoid class with confirmed ABCG2 inhibitory activity; combined with S-phase arrest, apoptosis induction, and anti-metastatic activity in multiple cancer cell lines; cancer adjuvant potential through resistance reversal

🦠

Triple anti-HBV mechanism: 90% ethanolic extract simultaneously inhibits HBV surface antigen AND HBV DNA polymerase AND induces IFN-γ in PBMCs — the most mechanistically comprehensive natural anti-hepatitis-B profile in Ayurvedic pharmacology; relevant to the 296 million people globally with chronic HBV and the liver cancer it causes

🌱

Boeravinones — nature's unique rotenoid class: Boeravinones A–H are found only in Boerhavia diffusa — nowhere else in the plant kingdom; each member of this class has distinct and validated pharmacological activity: B (antioxidant kidney restoration), E (nephrotic syndrome NPHS1 inhibition), G and H (ABCG2 cancer resistance reversal); the unique pharmacological signature of a plant that evolved its own compound class

⚕️

Excellent safety profile; used as food vegetable in tribal communities; no toxicity up to 5000 mg/kg; generations of safe use. Key precautions: avoid therapeutic doses in pregnancy (antifertility activity at high doses in animal models); additive effects with prescribed diuretics, antihypertensives, and antidiabetics — monitor clinical parameters; those with severe CKD (eGFR<30) need nephrologist guidance; authenticate B. diffusa by HPTLC boeravinone fingerprint

References

  1. PMC4053255 — Sood, A. et al. 'Phytochemical, therapeutic, and ethnopharmacological overview for a traditionally important herb: Boerhavia diffusa Linn', Advances in Botany. [Nyctaginaceae family; roots — novel isoflavonoid rotenoids (Boeravinones A–H), alkaloids, flavonoid glycosides, xanthones, purine nucleoside, lignans, ecdysteroids, steroids; diuresis, hepatoprotection, antifibrinolysis, anticancer, antidiabetic, anti-inflammation confirmed; more than 35 Ayurvedic formulations contain it as major ingredient; named for Hermann Boerhaave (Dutch physician 18th century); Atharvaveda root stock regeneration seasonal biology documented; official Indian Pharmacopoeia diuretic designation; ascites, anasarca, dropsy, kidney troubles, urinary stones, swelling formulations routinely; ACE inhibitor activity; congestive heart failure mechanism]. Also: Academia.edu review — punarnavine, hypoxanthine 9-L-arabinofuranoside, hentriacontane, β-sitosterol, boerhavin, boerhavic acid, various fatty acids, arginine, aspartic acid, glutamic acid documented; diuretic, anti-inflammatory, hepatoprotective, anti-fibrinolytic, anti-cancer, anti-diabetic, immunomodulatory, immuno-suppressive, anti-lymphoproliferative, analgesic, anti-TB confirmed.
  2. Correlation between phytocompounds and pharmacological activities of B. diffusa Linn, ScienceDirect 2022 (Phytochemistry 2022 review). Also: Ask-Ayurveda.com pharmacological review — Boeravinones A–G rotenoid derivatives; diuretic, hepatoprotective, antioxidant (J. Ethnopharmacol. 2005 reference); punarnavine anti-inflammatory immunomodulatory (Phytomedicine 2012 reference — IL-1β, TNF-α inhibition); betaine osmoprotectant fluid-electrolyte balance; saponins GFR diuresis mechanism; flavonoids quercetin kaempferol renal antioxidant free radical scavenging; synergistic Boeravinone + punarnavine + flavonoid diuresis without sodium loss; electrolyte-sparing comparison to furosemide/thiazides. Also: IJPCA 2021 — nephroprotective activity review; Rawat AKS, Mehrotra S, Tripathi SC, Shome U (1997) hepatoprotective B. diffusa roots, J Ethnopharmacol 56:61–66 [summer 1–3 cm roots aqueous extract; GOT, GPT, ACP, ALP protection; aqueous > powder form].
  3. Classical Ayurvedic documentation: Atharvaveda — Punarnava named for seasonal renewal (root stock dormancy and monsoon regeneration); Charaka Samhita — Svitkara Dravya (fluid-clearing), Shotha (oedema) primary herb, Prameha, Panduroga; Mutra Vishodhana (urinary purification); Sushruta Samhita — dropsy, abdominal oedema root decoction, "alleviating water retention without depleting essential salts"; Shothaghni synonym ("destroyer of swelling"); Mutravirajaniya (urinary purifier); Shweta Punarnava (B. diffusa) vs Rakta Punarnava (B. verticillata/red subspecies); two-variety classical classification; Ask-Ayurveda.com historical documentation — Charaka Samhita "mutra vishodhana" designation; Sushruta Samhita dropsy recommendation. Also: PMC10682173 (Frontiers Chem 2023) — "old root stock remains dormant during summer and regenerates during the rain"; Rasayan classification for anti-aging property (Wahi et al. 1997); immunity boosting, reestablishing youthfulness, strengthening body and mind (Samhita and Varanasi 1998); used in Ayurveda as rejuvenator in Asia and Africa.
  4. PMC10682173 — Frontiers in Chemistry 2023, 'Ethnomedicinal values of Boerhaavia diffusa L. as a panacea against multiple human ailments'. [Boeravinones G and H BCRP/ABCG2 efflux inhibitors — Ahmed-Belkacem et al. 2007; Boeravinone E NPHS1 inhibitor nephrotic syndrome — Colloids Surfaces B Biointerfaces 2023; liriodendrin and syringaresinol lignans; eupalitin novel C-methylflavone; quercetin-3-O-rutinoside anti-HIV integrase IC50 10 μg/ml; anti-quorum sensing B. diffusa against P. aeruginosa PAO1 (Shravani et al. 2023); oncoprotective chemopreventive anticancer evidence 2013–2023 table; B. diffusa Boeravinone B antioxidant (SOD, catalase, GPx, GSH) in EG hyperoxaluria model (reference 37 — Boeravinone B restoration of antioxidant system MDA, Catalase, GPx, GSH, GST, SOD)]. Also: PMC9105516 — anti-obesity via cannabinoid receptor (CB1) — Punarnavine, Boeravinone B, Eupalitin docked to cannabinoid receptor PDB 5TGZ; ADMET analysis favourable drug-like properties; Lipinski's rule satisfied. Punarnavine NK cell stimulation, IL-2 IFN-γ enhancement, ADCC enhanced, IL-1β IL-6 TNF-α reduced (Manu and Kuttan 2007 — ScienceDirect Topics reference).
  5. Singh, R.G., Kumar, G., Singh, S.K., Tripathi, Y.B. and Singh, R.H. (2010) 'Evaluation of antiproteinuric and renoprotective effect of Punarnava (Boerhavia diffusa Linn.) in diabetic nephropathy', Journal of Research and Education in Indian Medicine, 16(1–2):45–48. [Human clinical study; diabetic nephropathy patients with proteinuria >500 mg/day, serum creatinine <0.001 baseline; Punarnava dietary supplementation 6 months; significant decrease in urine protein; serum creatinine normalised; clinical renoprotection markers validated]. Also: IJPCA 2021 nephroprotective review — comprehensive summary of Boerhavia diffusa kidney protection studies including cisplatin acute kidney injury model (urea, creatinine, uric acid, BUN normalisation; LPO in kidney normalised; ion concentration normalised), Kalaivani et al. 2015 LLC-PK1 renal epithelial cell nephroprotection against cisplatin. Also: Chauhan aqueous extract 0.5% 50% crystal size reduction and 1.0% complete dissolution of ammonium magnesium phosphate hexahydrate kidney stones (gel-liquid interface method).
  6. Surya et al. — pulmonary tuberculosis adjuvant study: 25 patients Punarnava + chemotherapy vs 25 controls chemotherapy alone; 2-month follow-up; significantly faster clinical recovery, radiological clearing, sputum conversion; more weight gain; higher T lymphocyte count confirmed. (Reported in: phytopharmajournal.com Vol5 Issue2 review of B. diffusa and IJPCA 2021 nephroprotective review). Also: ScienceDirect Topics — B. diffusa anti-TB evidence: alkaloids furanolactone, palmatine, tinosporin, jatorrhizin, columbin active against M. tuberculosis, M. leprae; bacterial clearance improvement in mice models. Heliyon 2024 — B. diffusa anti-cancer, anti-quorum sensing properties; Gunaseelan et al. 2022 anticancer approaches for B. diffusa root extracts in oral cancer. WHO TB data: 10.6 million new TB cases, 1.3 million deaths annually (2022).
  7. Ahmed-Belkacem, A. et al. (2007) — Boeravinones G and H identified as efflux inhibitors of BCRP/ABCG2 (breast cancer resistance protein); multidrug transporter ABCG2 inhibition sensitising cancer cells to chemotherapy; first confirmation of natural rotenoid class as ABCG2 inhibitors. (Referenced in PMC10682173 Frontiers Chem 2023 review). Also: Sreeja and Sreeja (2009) — MCF-7 breast cancer cell viability reduction, G0/G1 arrest by methanolic whole plant extract; Srivastava et al. — HeLa and U-87 cytotoxicity confirmed; Leyon et al. (2005) — anti-metastatic B16F10 melanoma C57BL/6 mice, serum metastasis parameters reduced; Chopra et al. (2011) — cervical cancer HeLa cell growth inhibition confirmed. ScienceDirect Topics — oncoprotective and chemopreventive properties summary (B. diffusa); "anticancer activity proved" against multiple tested cancer cell lines; S-phase inhibition and apoptosis mechanism. PMC10682173 — boeravinones G and H BCRP ABCG2 citation confirmed; relevant reports published between 2013 and 2023 presented in Table 4.
  8. Rawat, A.K.S., Mehrotra, S., Tripathi, S.C. and Shome, U. (1997) 'Hepatoprotective activity of Boerhavia diffusa L. roots — a popular Indian ethnomedicine', Journal of Ethnopharmacology, 56:61–66. PMID 9147255. [Thioacetamide intoxicated rats; summer roots 1–3 cm diameter aqueous extract 2 ml/kg; GOT, GPT, ACP, ALP protection; aqueous > powder form; most desirable results with summer-harvested 1–3 cm roots]. Also: Chandan, B.K., Sharma, A.K. and Anand, K.K. (1991) 'Boerhaavia diffusa: a study of its hepatoprotective activity', J Ethnopharmacol, 31(3):299–307. Also: Kannan et al. (2011) — 90% EtOH root extract 5 mg/ml HBV surface antigen inhibition AND HBV DNA polymerase inhibition; 200 μg/ml IFN-γ induction in PBMCs (Th1 antiviral cytokine); PHA 5 μg/ml positive control; "B. diffusa contains anti-HBV substance(s)." (ScienceDirect Topics Boerhavia diffusa overview). Also: quercetin-3-O-rutinoside anti-HIV integrase IC50 10 μg/ml (ScienceDirect Topics). Asian J Agric Biol 2026 — rutin 0.42 mg/g, quercetin 0.31 mg/g, chlorogenic 0.25 mg/g, gallic 0.18 mg/g, caffeic 0.12 mg/g acids by HPLC in 70% ethanolic extract; TPC 34 mg GAE/g, TFC 60.52 μg CE/mL; DPPH 24.31% inhibition.
  9. Chauhan and co-workers — gel-liquid interface crystal growth model; ammonium magnesium phosphate hexahydrate (struvite) crystals; 0.5% aqueous extract → 50% size reduction; 1.0% aqueous extract → complete dissolution. (IJPCA 2021 nephroprotective review — source confirmation). Also: Boeravinone B renal antioxidant system restoration (MDA, Catalase, GPx, GSH, GST, SOD) in ethylene glycol hyperoxaluria nephrolithiasis model (ResearchGate nephroprotective role review 2023). Vanillic acid crystal aggregation inhibitory effect on struvite and apatite confirmed (Torzewska et al. in vitro, cited IJPCA). Hypoxanthine 9-L-arabinofuranoside biomineralisation recurrence inhibition and osmoregulatory role (ResearchGate review). Indian Pharmacopoeia official designation — formulations routinely used in ascites, anasarca, dropsy, kidney troubles, urinary stones, swelling of legs (PMC4053255).
  10. Hiruma-Lima et al. — acute oral toxicity study; lyophilized decoction (DE) and fresh leaf juice (JE); no sign of toxicity up to 5000 mg/kg; acute toxicity confirmed absent at highest dose tested (phytopharmajournal.com Vol5 Issue2 review). Also: Gharate, M. and Kasture, V. (2013) 'Evaluation of anti-inflammatory, analgesic, antipyretic and antiulcer activity of Punarnavasava: an Ayurvedic formulation of Boerhavia diffusa', Orient Pharm Exp Med, 13:121–126. [Punarnavasava classical formulation validated anti-inflammatory, analgesic, antipyretic, antiulcer]. Also: Handa and Jindal (2023, Environ Sci Pollut Res) — B. diffusa leaf extract mitigating nephrotoxic impact of hexavalent chromium in grass carp — further nephroprotective validation in toxicological context. Also: food vegetable use in tribal communities across India — generations of food-grade safe consumption at leaf/whole plant level documented.
Disclaimer: The information in this article is for educational purposes only and does not constitute medical advice. Most of the mechanistic evidence for Punarnava is from preclinical studies; the strongest human clinical evidence is the diabetic nephropathy 6-month study and the TB adjuvant trial. Do not replace prescribed diuretics, antidiabetic medications, antihypertensives, or TB treatment regimens with Punarnava supplementation without medical supervision. Avoid therapeutic doses during pregnancy. Monitor fluid status and electrolytes carefully if combining with prescribed diuretics. Authenticate B. diffusa species by HPTLC. The ABCG2 inhibition and anti-HBV evidence is preclinical — do not use as primary cancer or antiviral treatment.
supaveda.com · Ingredient Series · Punarnava (Boerhavia diffusa) · References verified March 2026
Back to blog